Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2021
Event: Entry into a Material Definitive Agreement (License Agreement) with Ocuphire.
Key Financial Metrics
This filing reports a strategic transaction rather than periodic financial results. Specific revenue, profit, cash flow, or margin data for the reporting period is not provided in this document.
- Upfront Consideration: $200,000 cash deposited into an escrow account.
- Equity Consideration: Shares of Processa common stock valued at $300,000 (calculated based on the 30-day VWAP).
- Future Obligations: Development, regulatory, and sales milestone payments; royalties on annual licensing sales; and 32% of sub-license milestone payments.
Material Changes
The primary material change is the acquisition of an exclusive global license (excluding China) to develop, manufacture, and commercialize the asset RX-3117 from Ocuphire. This expands Processa's product pipeline and introduces new contractual financial obligations.
Guidance, Outlook, and Risks
Management Commentary & Diligence Milestones: Processa is required to use commercially reasonable efforts to commercialize the product. Specific diligence milestones include:
- First patient dosed in a Clinical Trial within 3 years of the effective date.
- First patient dosed in a Pivotal Clinical Trial or a Clinical Trial for a Second Indication within 5 years of the effective date.
Risks and Contingencies:
- Termination: Either party may terminate the agreement for a material breach if not cured within 120 days of written notice.
- Financial Contingency: Future cash outflows depend on achieving specific clinical and regulatory milestones.
Investor Verification Checklist
- Verify the exact number of shares issued to Ocuphire based on the 30-day VWAP calculation.
- Review the full text of the License Agreement (Exhibit 10.1) for specific definitions of milestone triggers and royalty rates.
- Confirm the status of the $200,000 escrow deposit.
- Assess the impact of the new equity issuance on existing shareholder dilution.